These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 31048012)

  • 1. Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma.
    Sciullo PD; Menay F; Cocozza F; Gravisaco MJ; Waldner CI; Mongini C
    Clin Immunol; 2019 Jun; 203():154-161. PubMed ID: 31048012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
    Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ
    J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
    Gatza E; Okada CY
    J Immunol; 2002 Nov; 169(9):5227-35. PubMed ID: 12391241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant.
    Adams S; O'Neill DW; Nonaka D; Hardin E; Chiriboga L; Siu K; Cruz CM; Angiulli A; Angiulli F; Ritter E; Holman RM; Shapiro RL; Berman RS; Berner N; Shao Y; Manches O; Pan L; Venhaus RR; Hoffman EW; Jungbluth A; Gnjatic S; Old L; Pavlick AC; Bhardwaj N
    J Immunol; 2008 Jul; 181(1):776-84. PubMed ID: 18566444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40.
    Ruybal P; Gravisaco MJ; Barcala V; Escalada A; Di Sciullo P; Waldner C; Mongini C
    Vaccine; 2008 Jan; 26(5):697-705. PubMed ID: 18155328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imiquimod enhances the potency of an exogenous BM-DC based vaccine against mouse melanoma.
    Ren S; Wang Q; Zhang Y; Song Y; Dong X; Zhang W; Qin X; Liu M; Yu T
    Int Immunopharmacol; 2018 Nov; 64():69-77. PubMed ID: 30149266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophosphamide enhances the release of tumor exosomes that elicit a specific immune response in vivo in a murine T-cell lymphoma.
    Cocozza F; Menay F; Tsacalian R; Elisei A; Sampedro P; Soria I; Waldner C; Gravisaco MJ; Mongini C
    Vaccine; 2019 Mar; 37(12):1565-1576. PubMed ID: 30777349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.
    Mauldin IS; Wages NA; Stowman AM; Wang E; Olson WC; Deacon DH; Smith KT; Galeassi N; Teague JE; Smolkin ME; Chianese-Bullock KA; Clark RA; Petroni GR; Marincola FM; Mullins DW; Slingluff CL
    Cancer Immunol Immunother; 2016 Oct; 65(10):1201-12. PubMed ID: 27522582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant IL-15 does not enhance the efficacy of tumor cell lysate-pulsed dendritic cell vaccines for active immunotherapy of T cell lymphoma.
    Gatza E; Okada CY
    Cancer Immunol Immunother; 2006 Apr; 55(4):420-32. PubMed ID: 16025264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40.
    Khong A; Cleaver AL; Fahmi Alatas M; Wylie BC; Connor T; Fisher SA; Broomfield S; Lesterhuis WJ; Currie AJ; Lake RA; Robinson BW
    BMC Cancer; 2014 Dec; 14():969. PubMed ID: 25518732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine.
    Craft N; Bruhn KW; Nguyen BD; Prins R; Lin JW; Liau LM; Miller JF
    J Immunol; 2005 Aug; 175(3):1983-90. PubMed ID: 16034143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists.
    Triozzi PL; Aldrich W; Ponnazhagan S
    Vaccine; 2010 Nov; 28(50):7837-43. PubMed ID: 20937315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles.
    Bocanegra Gondan AI; Ruiz-de-Angulo A; Zabaleta A; Gómez Blanco N; Cobaleda-Siles BM; García-Granda MJ; Padro D; Llop J; Arnaiz B; Gato M; Escors D; Mareque-Rivas JC
    Biomaterials; 2018 Jul; 170():95-115. PubMed ID: 29656235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
    Soares MM; Mehta V; Finn OJ
    J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TCR vaccines against T cell lymphoma: QS-21 and IL-12 adjuvants induce a protective CD8+ T cell response.
    Wong CP; Okada CY; Levy R
    J Immunol; 1999 Feb; 162(4):2251-8. PubMed ID: 9973501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor IgE adjuvanticity: key role of Fc epsilon RI.
    Nigro EA; Brini AT; Soprana E; Ambrosi A; Dombrowicz D; Siccardi AG; Vangelista L
    J Immunol; 2009 Oct; 183(7):4530-6. PubMed ID: 19748979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-glioma effect of intracranial vaccination with tumor cell lysate plus flagellin in mice.
    Dong B; Wang L; Nie S; Li X; Xiao Y; Yang L; Meng X; Zhao P; Cui C; Tu L; Lu W; Sun W; Yu Y
    Vaccine; 2018 Dec; 36(52):8148-8157. PubMed ID: 30449633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.